Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00225979
Status:
COMPLETED
Last Update Posted:
2012-04-11
First Post:
2005-09-23
Brief Title:
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs Surgery in Treatment-naïve Patients With Acromegaly
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs Surgery in Treatment-naïve Patients With Acromegaly
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Currently the first line treatment for acromegaly is surgery in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly The objective of this study is to assess the safety and efficacy of long-acting repeatable formulation of octreotide and to compare it to the safety and efficacy of surgery in patients with acromegaly who have not had any previous treatment for acromegaly
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None